Scholarlink

<p>Locally advanced head and neck squamous cell carcinoma (LAHNSCC) unresectable at presentation has a dismal survival when radical surgery or definitive chemoradiation is not possible. This ambispective cohort study evaluated the addition of low-dose nivolumab to induction chemotherapy (IC) for locally advanced, unresectable or borderline resectable HNSCC. 111 patients with stage III-IVB disease received IC with low-dose nivolumab (&lt; 240&#xa0;mg or &lt; 3&#xa0;mg kg<sup>−1</sup> biweekly). The median nivolumab dose was 0.51&#xa0;mg kg<sup>−1</sup> biweekly, with a median of 3 doses. Overall response rate per RECIST v1.1 was 75.3% among evaluable patients. 31.6% of oral cavity tumours were rendered resectable, with 32% achieving pathological complete response (pCR). In other sites, the conversion rate to radical chemoradiation was 68.8%. One-year progression-free survival and overall survival were 67% and 83%, respectively, with post-induction radical therapy (<i>p</i> &lt; 0.001) and pCR/radiologic complete response (<i>p</i> &lt; 0.01) correlating with significantly longer PFS. Grade ≥ 3 adverse events occurred in 31.5% of patients. The nivolumab cost was reduced by 88.9% relative to standard dosing. These encouraging conversion rates to definitive therapy, highlight the potential of chemoimmunotherapy as induction therapy in this cohort with a very poor prognosis, with broader implications of cost savings where access to immune checkpoint inhibitors is limited.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Low-dose nivolumab plus induction chemotherapy for locally advanced or unresectable head and neck cancer is associated with high response rates and conversion to definitive therapy

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2025年10月8日

查看全文
  • Josh Thomas Georgy,
  • Soumya Susan Regi,
  • Rosh Varghese Georgy,
  • Balu Krishna Sasidharan,
  • Anjana Joel,
  • Deepa Susan Joy Philip,
  • Ajoy Oommen John,
  • Divya Bala Thumaty,
  • Praveen Kumar Marimuthu,
  • Prashant Jambunathan,
  • Kovilapu Harikrishna,
  • Zachariah Thomas,
  • N. Jansi Rani,
  • Amit Jiwan Tirkey,
  • Meera Thomas,
  • Rajesh Isiah,
  • Ashish Singh

摘要

Locally advanced head and neck squamous cell carcinoma (LAHNSCC) unresectable at presentation has a dismal survival when radical surgery or definitive chemoradiation is not possible. This ambispective cohort study evaluated the addition of low-dose nivolumab to induction chemotherapy (IC) for locally advanced, unresectable or borderline resectable HNSCC. 111 patients with stage III-IVB disease received IC with low-dose nivolumab (< 240 mg or < 3 mg kg−1 biweekly). The median nivolumab dose was 0.51 mg kg−1 biweekly, with a median of 3 doses. Overall response rate per RECIST v1.1 was 75.3% among evaluable patients. 31.6% of oral cavity tumours were rendered resectable, with 32% achieving pathological complete response (pCR). In other sites, the conversion rate to radical chemoradiation was 68.8%. One-year progression-free survival and overall survival were 67% and 83%, respectively, with post-induction radical therapy (p < 0.001) and pCR/radiologic complete response (p < 0.01) correlating with significantly longer PFS. Grade ≥ 3 adverse events occurred in 31.5% of patients. The nivolumab cost was reduced by 88.9% relative to standard dosing. These encouraging conversion rates to definitive therapy, highlight the potential of chemoimmunotherapy as induction therapy in this cohort with a very poor prognosis, with broader implications of cost savings where access to immune checkpoint inhibitors is limited.